Somapacitan not checked

Novo Nordisk · NNC0195-0092

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
None yet
 
Trials
3 active
6 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.”In the company’s words, NCT05723835 on ClinicalTrials.gov
Tested for
SGA, Turner Syndrome, Noonan Syndrome, ISS, SGA, Turner Syndrome, Noonan Syndrome, ISS, Short Stature Children Born Small for Gestational Age (SGA)
Main trialPhase 3
“The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nurse will show how to inject somapacitan, so that the participant knows how to do it at home.”In the company’s words, NCT05723835 on ClinicalTrials.gov
Other names
NNC0195-0092

Other drugs for Turner Syndrome

All 3 drugs for Turner Syndrome

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 7 Jun 2024 A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Phase 3Active, not recruiting 5 Aug 2024 A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Phase 2Active, not recruiting 5 May 2021 A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
Phase 3Completed 10 Nov 2021 A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Phase 3Completed 17 Nov 2023 A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Phase 2Completed 26 Sep 2024 Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Somapacitan

Following is part of Solo: you see every change to Somapacitan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in